FDA Clears IND for UX016 in GNE Myopathy, Phase 1/2 Study Expected H2 2026
RARE is trading near its 52-week low of $18.29 (9.3% above the low).
Summary
Ultragenyx Pharmaceutical announced FDA clearance for its Investigational New Drug (IND) application for UX016, a potential treatment for GNE myopathy, with a Phase 1/2 study planned for the second half of 2026, supported by external funding.
Key Events · Product Development and Regulatory · RARE
-
FDA IND Clearance for UX016
The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for UX016, a small molecule prodrug for GNE myopathy (GNEM).
-
Externally Funded Program
The UX016 program is externally funded by a patient group through clinical proof-of-concept, including the upcoming Phase 1/2 study, reducing Ultragenyx's direct R&D expense.
-
Phase 1/2 Study Planned
A first-in-human Phase 1/2 study for UX016, enrolling approximately 24 adults with GNEM, is expected to begin in the second half of 2026 to evaluate safety and efficacy.
Analysis · RARE · Life Sciences
This 8-K confirms the FDA's clearance of the Investigational New Drug (IND) application for UX016, a significant step forward for Ultragenyx's pipeline, especially following recent setbacks with other programs as noted in the last 10-K. The external funding for the UX016 program through clinical proof-of-concept reduces the company's financial risk while advancing a potential treatment for GNE myopathy, a rare and debilitating neuromuscular disorder. The planned Phase 1/2 study in the second half of 2026 will evaluate the safety and efficacy of UX016, which is designed to improve drug delivery to muscle compared to prior therapies. This development provides a positive catalyst for the company's drug development efforts.
At the time of this filing, RARE was trading at $20.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $18.29 to $42.37. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.